Gilead’s Covid-19 Drug is Mediocre. It Will Be a Blockbuster Anyway.
Gilead Sciences said Wednesday that remdesivir, which has been authorized for emergency use since the spring, brought in $873 million in revenues so far this year.
from NYT > Health https://ift.tt/31QSZsg
via health&fitness
Aucun commentaire:
Enregistrer un commentaire